Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome

YILMAZ S., ÖZÇAKAR Z. B., Taktak A., KİREMİTCİ S., ENSARİ A., DİNÇASLAN H., ...Daha Fazla

PEDIATRIC NEPHROLOGY, cilt.31, sa.6, ss.1029-1032, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 31 Sayı: 6
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1007/s00467-016-3355-z
  • Dergi Adı: PEDIATRIC NEPHROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1029-1032
  • Anahtar Kelimeler: Thrombotic microangiopathy, Bevacizumab, Anti-VEGF, Nephrotic syndrome, Child, TARGETED THERAPY, BEVACIZUMAB, ANGIOGENESIS, INHIBITION, SORAFENIB, TOXICITY
  • Ankara Üniversitesi Adresli: Evet

Özet

Targeting the vascular endothelial growth factor (VEGF) signaling pathway has become an important approach to current cancer therapy. Anti-VEGF therapy-related renal adverse effects may present as hypertension, non-nephrotic proteinuria, and rarely as nephrotic syndrome (NS) and acute kidney injury.